New therapies for chronic hepatitis C virus infection

被引：15
作者：
Dev A. [1 ]
Patel K. [1 ]
McHutchison J.G. [1 ]
机构：
[1] Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715
来源：
Current Gastroenterology Reports | 2004年 / 6卷 / 1期
关键词：
Chronic Hepatitis; Amantadine; Stellate Cell Activation; Histamine Dihydrochloride;
D O I：
10.1007/s11894-004-0030-5
中图分类号：
学科分类号：
摘要：
Chronic hepatitis C infection is associated with significant morbidity and mortality in addition to substantial social and health-related costs. Since the identification of the virus and determination of the HCV genome over a decade ago, considerable progress has been made in the treatment of chronic hepatitis C infection. However, the current standard combination of interferon-based therapies and ribavirin is effective in only 50% of patients. In addition, this combination is expensive, requires lengthy periods of administration, and is associated with significant side effects. Furthermore, no effective preventive measure, such as vaccination, is currently available. A number of newer therapies, including protease and helicase inhibitors, ribozymes, antisense therapies, and therapeutic vaccines, are in preclinical and clinical development and may significantly enhance existing therapeutic options for the future. Copyright © 2004 by Current Science Inc.
引用
收藏
页码：77 / 86
页数：9
相关论文
共 61 条
[1]  
Hepatitis C: Global prevalence, Wkly. Epidemiol. Rec., 49, pp. 425-427, (1999)
[2]  
Cooreman M.P., Schoondermark-Van De Ven E.M., Hepatitis C virus: Biological and clinical consequences of genetic heterogeneity, Scand. J. Gastroenterol., 218, SUPPL., pp. 106-115, (1996)
[3]  
Di Bisceglie A.M., Natural history of hepatitis C: Its impact on clinical management, Hepatology, 31, pp. 1014-1018, (2000)
[4]  
Khan M., Farrell G., Byth K., Et al., Which patients with hepatitis C develop liver complications?, Hepatology, 31, pp. 513-520, (2000)
[5]  
Detre K.M., Belle S.H., Lombardero M., Liver transplantation for chronic viral hepatitis, Viral Hepat. Rev., 2, pp. 219-228, (1997)
[6]  
Simmonds P., Alberti A., Alter H.J., Et al., Second international conference of HCV and related viruses, Hepatology, 19, pp. 1321-1324, (1994)
[7]  
Grakoui A., Mccourt D.W., Wychowski C., Et al., Characterization of the hepatitis C virus-encoded serine proteinase: Determination of proteinase-dependent polyprotein cleavage sites, J. Virol., 67, pp. 2832-2843, (1993)
[8]  
Gwack Y., Kim D.W., Han J.H., Characterization of RNA binding activity and RNA helicase activity of the hepatitis C virus NS3 protein, Biochem. Biophys. Res. Commun., 225, pp. 654-659, (1996)
[9]  
Hwang L.H., Hsieh C.L., Yen A., Et al., Involvement of the 5′ proximal coding sequences of hepatitis C virus with internal initiation of viral translation, Biochem. Biophys. Res. Commun., 252, pp. 455-460, (1998)
[10]  
McHutchison J.G., Gordon S.C., Schiff E.R., Et al., Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C, N. Engl. J. Med., 339, pp. 1485-1492, (1998)
1234567